Sign up to save your podcasts
Or
Share Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Symptomatic Heart Failure Patients: RESHAPE-HF2 Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Symptomatic Heart Failure Patients: RESHAPE-HF2 Trial
The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure [HF]: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation [MR]) trial assessed the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic HF patients with secondary MR. The results of this trial indicate that M-TEER using the MitraClip on a background of maximally tolerated guideline-directed medical therapy (GDMT) was superior to GDMT alone in reducing HF hospitalization and mortality at 2 years in symptomatic HF patients with grade 3-4+ MR.
In this interview, Drs. Sidney Smith and Stefan Anker discuss the benefits of RESHAPE-HF2, including reduction in HF hospitalization (particularly among those with a history of HF hospitalization within the past year), significant quality-of-life improvements, and other patient-centered outcomes.
References:
-
Anker SD, Friede T, von Bardeleben RS, et al., for the RESHAPE-HF2 Investigators. Transcatheter Valve Repair in Heart Failure With Moderate to Severe Mitral Regurgitation. N Engl J Med 2024;Aug 31:[Epub ahead of print].
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
View all episodes
By American College of Cardiology
3.8
4747 ratings
The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure [HF]: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation [MR]) trial assessed the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic HF patients with secondary MR. The results of this trial indicate that M-TEER using the MitraClip on a background of maximally tolerated guideline-directed medical therapy (GDMT) was superior to GDMT alone in reducing HF hospitalization and mortality at 2 years in symptomatic HF patients with grade 3-4+ MR.
In this interview, Drs. Sidney Smith and Stefan Anker discuss the benefits of RESHAPE-HF2, including reduction in HF hospitalization (particularly among those with a history of HF hospitalization within the past year), significant quality-of-life improvements, and other patient-centered outcomes.
References:
-
Anker SD, Friede T, von Bardeleben RS, et al., for the RESHAPE-HF2 Investigators. Transcatheter Valve Repair in Heart Failure With Moderate to Severe Mitral Regurgitation. N Engl J Med 2024;Aug 31:[Epub ahead of print].
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
JAMA Editors' Summary
130 Listeners
NEJM This Week
319 Listeners
JACC Podcast
160 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
494 Listeners
JACC Specialty Journals
21 Listeners
Circulation on the Run
32 Listeners
JAMA Medical News
87 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
135 Listeners
Core IM | Internal Medicine Podcast
1,081 Listeners
ACC CardiaCast
39 Listeners
Annals On Call Podcast
186 Listeners
Cardionerds: A Cardiology Podcast
414 Listeners
Mayo Clinic Cardiovascular CME
35 Listeners
Sensible Medicine
136 Listeners